REDWOOD CITY, Calif.– Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company’s Chief Scientific Officer.
“I am excited to welcome Frank to the Meissa leadership team,” said Dr. Moore. “We are at an important stage in Meissa’s growth, and Frank brings extensive, complementary experience in commercial planning, business development, and pipeline strategy to advance novel technologies in clinical development for regulatory approval. I look forward to continuing to work with Frank and the Meissa team to drive our platform and vaccine candidates forward.”
“I’ve been working closely with Marty and the team as an advisor, and I am impressed with the differentiation of Meissa’s AttenuBlock platform in the vaccine space and the tremendous progress the company has made,” said Mr. Glavin. “The initial clinical data from the RSV and COVID-19 programs demonstrate the enormous potential of Meissa’s AttenuBlock platform to develop intranasal vaccines to protect against respiratory viruses, and we look forward to completing enrollment in these studies and reporting the data in the first half of next year.”
Mr. Glavin was previously CEO of Orphan Technologies, which advanced two rare disease assets from the lab to the clinic culminating in a sale to Travere Therapeutics (Nasdaq: TVTX). In addition, he was the Head of Neovii Biotech North America, where he was responsible for clinical development, regulatory approval, and commercialization of the US portfolio.
